RCUS Forecast


Bullish Case: RCUS has strong insider ownership and historical price increases. High institutional investment and potential positive Phase 3 results for domvanalimab support a bullish case.


Bearish Case: High R&D expenses and potential dilution from a capital raise are significant concerns. Competitive pressures in the anti-TIGIT market could also limit upward momentum.


Potential Outcomes:

1) Domvanalimab succeeds in Phase 3 trials: 45%, major upside.

2) Capital raise: 20%, dilution risk.

3) Competitive market pressures: 25%, limited gain.

4) Failure of Phase 3 or unforeseen adverse effects: 10%, significant downside risk.


Trading Oracle: Sign Up to access trading oracle trade ideas.


July 21, 2024


Arcus Biosciences Forecast

RCUS      Arcus Biosciences











Correlated Assets

Assets that tend to move strongly with RCUS



LI Forecast + Options Trading Strategies   LI  Li Auto (0.53)


VFC Forecast + Options Trading Strategies   VFC  VF (0.48)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.08)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.15)



Uncorrelated Assets

Assets with little price relationship to RCUS



XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.08)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.15)


VFC Forecast + Options Trading Strategies   VFC  VF (0.48)


LI Forecast + Options Trading Strategies   LI  Li Auto (0.53)



Anticorrelated Assets

Assets that tend to move strongly against RCUS



LI Forecast + Options Trading Strategies   LI  Li Auto (0.53)


VFC Forecast + Options Trading Strategies   VFC  VF (0.48)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.08)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.15)





Become a more profitable investor with AI optimized trading strategies






×

Chat with RCUS


 Ask any question about RCUS!